| 摘要 |
<p>The present invention relates to use of the compound PM181104, or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, for the treatment of Clostridium difficile associated infections. The invention further relates to a pharmaceutical composition comprising the compound PM181104 and at least one pharmaceutically acceptable carrier, for use in the treatment of Clostridium difficile associated infections. The invention also relates to a method for the treatment of Clostridium difficile associated infections, comprising administering to a subject in need thereof, a therapeutically effective amount of the compound PM181104.</p> |
